This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Alimera Sciences Toekomstige groei
Future criteriumcontroles 4/6
Alimera Sciences is forecast to grow earnings and revenue by 115.1% and 11.4% per annum respectively.
Belangrijke informatie
115.1%
Groei van de winst
n/a
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 18.3% |
| Inkomstengroei | 11.4% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 18 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 125 | 13 | N/A | N/A | 2 |
| 12/31/2025 | 118 | 8 | N/A | N/A | 3 |
| 12/31/2024 | 106 | -6 | N/A | N/A | 3 |
| 6/30/2024 | 100 | -15 | -6 | -6 | N/A |
| 3/31/2024 | 90 | -23 | -88 | -13 | N/A |
| 12/31/2023 | 81 | -21 | -90 | -14 | N/A |
| 9/30/2023 | 68 | -21 | -94 | -18 | N/A |
| 6/30/2023 | 59 | -25 | -86 | -10 | N/A |
| 3/31/2023 | 56 | -17 | -6 | -6 | N/A |
| 12/31/2022 | 54 | -18 | -10 | -10 | N/A |
| 9/30/2022 | 54 | -18 | -15 | -14 | N/A |
| 6/30/2022 | 53 | -17 | -16 | -15 | N/A |
| 3/31/2022 | 60 | -7 | -8 | -7 | N/A |
| 12/31/2021 | 59 | -4 | -4 | -3 | N/A |
| 9/30/2021 | 59 | -1 | 1 | 1 | N/A |
| 6/30/2021 | 59 | 2 | 1 | 2 | N/A |
| 3/31/2021 | 47 | -8 | -6 | -5 | N/A |
| 12/31/2020 | 51 | -5 | -3 | -2 | N/A |
| 9/30/2020 | 54 | -4 | -2 | -2 | N/A |
| 6/30/2020 | 55 | -6 | -4 | -3 | N/A |
| 3/31/2020 | 56 | -9 | -4 | -4 | N/A |
| 12/31/2019 | 54 | -10 | -4 | -4 | N/A |
| 9/30/2019 | 52 | -12 | -4 | -4 | N/A |
| 6/30/2019 | 50 | 19 | -4 | -4 | N/A |
| 3/31/2019 | 50 | 22 | -6 | -6 | N/A |
| 12/31/2018 | 47 | 17 | -12 | -12 | N/A |
| 9/30/2018 | 41 | 11 | -14 | -14 | N/A |
| 6/30/2018 | 39 | -22 | -14 | -14 | N/A |
| 3/31/2018 | 39 | -23 | N/A | -14 | N/A |
| 12/31/2017 | 36 | -22 | N/A | -13 | N/A |
| 9/30/2017 | 37 | -21 | N/A | -14 | N/A |
| 6/30/2017 | 36 | -25 | N/A | -18 | N/A |
| 3/31/2017 | 35 | -29 | N/A | -23 | N/A |
| 12/31/2016 | 34 | -33 | N/A | -25 | N/A |
| 9/30/2016 | 29 | -38 | N/A | -32 | N/A |
| 6/30/2016 | 28 | -30 | N/A | -32 | N/A |
| 3/31/2016 | 24 | -32 | N/A | -37 | N/A |
| 12/31/2015 | 22 | -31 | N/A | -45 | N/A |
| 9/30/2015 | 18 | -30 | N/A | -46 | N/A |
| 6/30/2015 | 14 | -35 | N/A | -42 | N/A |
| 3/31/2015 | 10 | -26 | N/A | -33 | N/A |
| 12/31/2014 | 8 | -37 | N/A | -24 | N/A |
| 9/30/2014 | 8 | -41 | N/A | -25 | N/A |
| 6/30/2014 | 6 | -36 | N/A | -29 | N/A |
| 3/31/2014 | 4 | -58 | N/A | -34 | N/A |
| 12/31/2013 | 2 | -51 | N/A | -38 | N/A |
| 9/30/2013 | 1 | -42 | N/A | -35 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ASZ1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Winst versus markt: ASZ1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: ASZ1 is expected to become profitable in the next 3 years.
Omzet versus markt: ASZ1's revenue (11.4% per year) is forecast to grow faster than the German market (5.5% per year).
Hoge groei-inkomsten: ASZ1's revenue (11.4% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if ASZ1's Return on Equity is forecast to be high in 3 years time